Integration of miRNA’s theranostic potential with nanotechnology: Promises and challenges for Parkinson’s disease therapeutics

• Published in: Mechanisms of ageing and development Vol. 211; p. 111800
• Main Authors: Tryphena, Kamatham Pushpa, Singh, Gurpreet, Jain, Naitik, Famta, Paras, Srivastava, Saurabh, Singh, Shashi Bala, Khatri, Dharmendra Kumar
• Format: Journal Article
• Language: English
• Published: Ireland Elsevier B.V 01.04.2023
• Subjects: Agomir; Antagomir; Biomarkers; Blood-Brain Barrier; Brain - pathology; Humans; MicroRNA; MicroRNAs - genetics; Nanoparticles; Parkinson Disease - diagnosis; Parkinson Disease - genetics; Parkinson Disease - therapy; Parkinson’s disease; Precision Medicine; RVG; BBB; ALP; LRRK2; JNK; Agomir; PTEN; 6-OHDA; PitX3; AUC; UTR; UPP; CMA; UPR; Hsp; DAPK1; SNpc; AXIN1; Nurr1; IGF-1; MAPK; ER; SIRT1; Biomarkers; FC; PRKN; BECN1; DRP-1; CNS; GLRX; LAMP2A; DRP1; Nanoparticles; GSK-3β; RIPK; Nrf2; PGC-α; NLRP3; Psmd3; VDAC-1; Antagomir; NPs; PINK1; MicroRNA; PD; Keap1; MPTP; PUMA; Parkinson’s disease
• ISSN: 0047-6374; 1872-6216
• DOI: 10.1016/j.mad.2023.111800

Despite the wide research going on in Parkinson’s disease (PD), the burden of PD still remains high and continues to increase. The current drugs available for the treatment of PD are only aimed at symptomatic control. Hence, research is mainly focused on identifying the novel therapeutic targets that can be effectively targeted in order to slow down or culminate the disease progression. Recently the role of microRNAs (miRNAs) in the regulation of various pathological mechanisms of PD has been thoroughly explored and many of them were found to be dysregulated in the biological samples of PD patients. These miRNAs can be used as diagnostic markers and novel therapeutic options to manage PD. The delivery of miRNAs to the target site in brain is a challenging job owing to their nature of degradability by endonucleases as well as poor blood brain barrier (BBB) permeability. Nanoparticles appear to be the best solution to effectively encase the miRNA in their core as well as cross the BBB to deliver them into brain. Functionalisation of these nanoparticles further enhances the site-specific delivery. [Display omitted] •miRNAs are involved in the regulation of various mechanisms implicated in the pathogenesis of Parkinson’s disease (PD).•Many miRNAs are found to be dysregulated in PD.•Circulatory miRNAs can be used as biomarkers in PD.•miRNA mimics and inhibitors could be potential therapeutic options to manage PD.•Nanotechnology offers a solution for the challenges related to miRNA delivery.•Nanoparticles can be used as carriers to deliver miRNA to target sites in the brain.